GenBody is a diversified manufacturer of diagnostic tests for over 78 human diseases. With more than 20 years combined experience in the diagnostic industry and through its vast network between several key institutes, universities and hospitals, our core strength is in R&D. GenBody specializes in developing monoclonal antibodies and recombinant antigens in-house at our facility in South Korea. Recently, the US FDA granted Emergency Use Authorization to GenBody's COVID-19 Ag point-of-care antigen test for SARS-CoV-2 infection. The immunochromatographic rapid diagnostic test is designed for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct nasopharyngeal swab specimens. The test can be performed by a healthcare professional and an at-home test is in development for future use. Earlier this year, GenBody received a US National Institutes of Health contract for the US production of a visually read, single lateral flow rapid test system for SARS-CoV-2. Located in Jurupa Valley, California, the US factory is expected to be complete in Q3 2021. GenBody is rapidly expanding its footprint in the US and expects to increase its headcount in regulatory, product development and sales. For inquires regarding opportunities join our team, please call 949-561-0664 or jobs@genbodyamerica.com. For partnership opportunities, call 949-561-0664 or email partnerships@genbodyamerica.com.